# A Phase I/III Study to Evaluate Efficacy, PK and Safety Between CT-P13 SC and CT-P13 IV in Patients With Active RA

> **NCT03147248** · PHASE3 · COMPLETED · sponsor: **Celltrion** · enrollment: 407 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **BIOLOGICAL:** CT-P13
- **BIOLOGICAL:** CT-P13
- **BIOLOGICAL:** CT-P13
- **BIOLOGICAL:** CT-P13
- **BIOLOGICAL:** CT-P13
- **BIOLOGICAL:** CT-P13

## Key facts

- **NCT ID:** NCT03147248
- **Lead sponsor:** Celltrion
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-09-12
- **Primary completion:** 2018-05-21
- **Final completion:** 2019-04-15
- **Target enrollment:** 407 (ACTUAL)
- **Last updated:** 2020-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03147248

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03147248, "A Phase I/III Study to Evaluate Efficacy, PK and Safety Between CT-P13 SC and CT-P13 IV in Patients With Active RA". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT03147248. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*